Dr. Raid Aljumaily
Claim this profileUniversity of Oklahoma Health Sciences Center
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
44 drugs studied
About Raid Aljumaily
Education:
- Graduated with an MD from the University of Baghdad College of Medicine, Iraq, in 2009.
- Completed a Residency in Internal Medicine at the University of Oklahoma Health Sciences Center in 2016.
- Finished a Fellowship in Hematology/Oncology at the University of Oklahoma Health Sciences Center in 2019.
Experience:
- Has been serving as an Assistant Professor of Medicine at the University of Oklahoma Health Sciences Center since 2019.
- Specializes in hematologic malignancies, lymphoma, and myelodysplastic syndromes.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Raid Aljumaily is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
IMC-F106C Combinations
for Solid Cancers
This trial tests IMC-F106C, a treatment that helps the immune system target and kill cancer cells in adults with advanced cancers. It guides immune cells to attack cancer cells more effectively.
Recruiting1 award Phase 1 & 2
More about Raid Aljumaily
Clinical Trial Related8 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Raid Aljumaily has experience with
- Carboplatin
- Pembrolizumab
- Pemetrexed
- Nivolumab
- Atezolizumab
- Paclitaxel
Breakdown of trials Raid Aljumaily has run
Lung Cancer
Non-Small Cell Lung Cancer
Parotid Gland Cancer
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Raid Aljumaily specialize in?
Is Raid Aljumaily currently recruiting for clinical trials?
Are there any treatments that Raid Aljumaily has studied deeply?
What is the best way to schedule an appointment with Raid Aljumaily?
What is the office address of Raid Aljumaily?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.